89Zr-panitumumab PET imaging for preoperative evaluation of ameloblastoma in a PDX mannequin
Ladeinde, A. L. et al. Odontogenic tumors: A overview of 319 circumstances in a Nigerian educating hospital. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 99(2), 191–195 (2005).
Johnson, N. R. et al. A potential epidemiological research for odontogenic and non-odontogenic lesions of the maxilla and mandible in Queensland. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 115(4), 515–522 (2013).
Amm, H. M. & MacDougall, M. Molecular signaling in Benign odontogenic neoplasia pathogenesis. Curr. Oral Well being Rep. 3(2), 82–92 (2016).
Laborde, A. et al. Ameloblastoma of the jaws: Administration and recurrence fee. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 134(1), 7–11 (2017).
Hong, J. et al. Lengthy-term comply with up on recurrence of 305 ameloblastoma circumstances. Int. J. Oral Maxillofac. Surg. 36(4), 283–288 (2007).
Almeida Rde, A. et al. Recurrence fee following therapy for major multicystic ameloblastoma: Systematic overview and meta-analysis. Int. J. Oral Maxillofac. Surg. 45(3), 359–367 (2016).
Sachs, S. A. Surgical excision with peripheral ostectomy: A definitive, but conservative, method to the surgical administration of ameloblastoma. J. Oral Maxillofac. Surg. 64(3), 476–483 (2006).
Vered, M., Shohat, I. & Buchner, A. Epidermal development issue receptor expression in ameloblastoma. Oral Oncol. 39(2), 138–143 (2003).
Goncalves, C. Okay. et al. Immunohistochemical expression of p63, epidermal development issue receptor (EGFR) and notch-1 in radicular cysts, dentigerous cysts and keratocystic odontogenic tumors. Braz. Dent. J. 23(4), 337–343 (2012).
Oikawa, M. et al. Evaluation of protein expression and gene standing of human epidermal development issue receptor (HER) household molecules in ameloblastomas. J. Oral Pathol. Med. 42(5), 424–434 (2013).
Kurppa, Okay. J. et al. Excessive frequency of BRAF V600E mutations in ameloblastoma. J. Pathol. 232(5), 492–498 (2014).
Abdel-Aziz, A. & Amin, M. M. EGFR, CD10 and proliferation marker Ki67 expression in ameloblastoma: Attainable function in native recurrence. Diagn. Pathol. 7, 14 (2012).
Siqueira, A. S. et al. Matrix metalloproteinases, TIMPs and development components regulating ameloblastoma behaviour. Histopathology 57(1), 128–137 (2010).
Morlandt, A. B. et al. Fluorescently labeled cetuximab-IRDye800 for guided surgical excision of ameloblastoma: A proof of precept research. J. Oral Maxillofac. Surg. 78(10), 1736–1747 (2020).
Rosenthal, E. L. et al. Security and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck most cancers. Clin. Most cancers Res 21(16), 3658–3666 (2015).
Giusti, R. M. et al. FDA drug approval abstract: Panitumumab (Vectibix). Oncologist 12(5), 577–583 (2007).
Chang, A. J., De Silva, R. A. & Lapi, S. E. Improvement and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal development issue receptor. Mol. Imaging 12(1), 17–27 (2013).
Binfield, P. In At PLoS ONE we’re batty about bats, in PLoS: Public Library of Science. 2008. p. Net log message.
Lindenberg, L. et al. Dosimetry and first human expertise with (89)Zr-panitumumab. Am. J. Nucl. Med. Mol. Imaging 7(4), 195–203 (2017).
Nayak, T. Okay. et al. PET and MRI of metastatic peritoneal and pulmonary colorectal most cancers in mice with human epidermal development issue receptor 1-targeted 89Zr-labeled panitumumab. J. Nucl. Med. 53(1), 113–120 (2012).
Bhattacharyya, S. et al. Zirconium-89 labeled panitumumab: A possible immuno-PET probe for HER1-expressing carcinomas. Nucl. Med. Biol. 40(4), 451–457 (2013).
Bhattacharyya, S. et al. Synthesis and organic analysis of panitumumab-IRDye800 conjugate as a fluorescence imaging probe for EGFR-expressing cancers. Med. Chem. Commun. 5(9), 1337–1346 (2014).
Warram, J. M. et al. Antibody-based imaging methods for most cancers. Most cancers Metastasis Rev. 33(2–3), 809–822 (2014).
Seeburg, D. P., Baer, A. H. & Aygun, N. Imaging of sufferers with head and neck most cancers: From staging to surveillance. Oral Maxillofac. Surg. Clin. N. Am. 30(4), 421–433 (2018).
Kolk, A. et al. Mixed SPECT/CT improves detection of preliminary bone invasion and dedication of resection margins in squamous cell carcinoma of the top and neck in comparison with standard imaging modalities. Eur. J. Nucl. Med. Mol. Imaging 41(7), 1363–1374 (2014).
Benedetto, R. et al. (89)Zr-DFO-cetuximab as a molecular imaging agent to establish cetuximab resistance in head and neck squamous cell carcinoma. Most cancers Biother. Radiopharm. 34(5), 288–296 (2019).
Gamoh, S. et al. The function of computed tomography and magnetic resonance imaging in diagnosing clear cell ameloblastoma: A case report. Oncol. Lett. 14(6), 7257–7261 (2017).
Konouchi, H. et al. Usefulness of distinction enhanced-MRI within the prognosis of unicystic ameloblastoma. Oral Oncol. 42(5), 481–486 (2006).
Li, D. et al. 3D cone beam computed tomography reconstruction pictures in prognosis of ameloblastomas of decrease jaw: A case report and mini overview. J. Xray Sci. Technol. 26(1), 133–140 (2018).
Seno, S. et al. FDG-PET findings of ameloblastoma: A case report. Springerplus 4, 250 (2015).
Niu, N. et al. A number of organ metastases from ameloblastoma detected by FDG PET/CT imaging. Clin. Nucl. Med. 38(12), 1009–1011 (2013).
Fernandes, G. S. et al. Scientific profit and radiological response with BRAF inhibitor in a affected person with recurrent ameloblastoma harboring V600E mutation. BMC Most cancers 18(1), 887 (2018).
Day, Okay. E. et al. Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma. Laryngoscope 123(11), 2681–2689 (2013).
Daramola, J. O., Ajagbe, H. A. & Oluwasanmi, J. O. Recurrent ameloblastoma of the jaws—a overview of twenty-two circumstances. Plast. Reconstr. Surg. 65(5), 577–579 (1980).
Carlson, E. R. & Marx, R. E. The ameloblastoma: Major, healing surgical administration. J. Oral Maxillofac. Surg. 64(3), 484–494 (2006).
Lopez, R. et al. Potential comparability of (18)F-NaF PET/CT versus (18)F-FDG PET/CT imaging in mandibular extension of head and neck squamous cell carcinoma with devoted evaluation software program and validation with surgical specimen. A preliminary research. J. Craniomaxillofac. Surg. 45(9), 1486–1492 (2017).
Lopez, R. et al. Worth of PET/CT 3D visualization of head and neck squamous cell carcinoma prolonged to mandible. J. Craniomaxillofac. Surg. 46(5), 743–748 (2018).
Stalder, S. A. et al. Worth of SUVmax for the predication of bone invasion in oral squamous cell carcinoma. Biology 9(2), 23–33 (2020).
Lubek, J. E. & Magliocca, Okay. R. Analysis of the bone margin in oral squamous cell carcinoma. Oral Maxillofac. Surg. Clin. N. Am. 29(3), 281–292 (2017).
Stalder, S. A. et al. Worth of SUVmax for the prediction of bone invasion in oral squamous cell carcinoma. Biol. (Basel) 9, 2 (2020).
McKnight, B. N. & Viola-Villegas, N. T. (89) Zr-ImmunoPET companion diagnostics and their affect in medical drug improvement. J. Label. Comp. Radiopharm. 61(9), 727–738 (2018).
Sivapathasundharam, B., Biswas, P. G. & Preethi, S. The World Well being Group classification of odontogenic and maxillofacial bone tumors: An appraisal. J. Oral Maxillofac. Pathol. 23(2), 178–186 (2019).
Queern, S. L. et al. Manufacturing of Zr-89 utilizing sputtered yttrium coin targets (89)Zr utilizing sputtered yttrium coin targets. Nucl. Med. Biol. 50, 11–16 (2017).
Warram, J. M. et al. Fluorescence imaging to localize head and neck squamous cell carcinoma for enhanced pathological evaluation. J. Pathol. Clin. Res. 2(2), 104–112 (2016).
Massicano, A. V. F. et al. Imaging of HER2 with [(89)Zr]pertuzumab in response to T-DM1 remedy. Most cancers Biother. Radiopharm. 34(4), 209–217 (2019).
McGregor, P. Okay., et al. In Design of Playback Experiments—The Thornbridge Corridor Nato ARW CONSENSUS. Playback and Research of Animals Communication, ed. P.Okay. McGregor. vol. 228, 1–9 (Plenum Press Div Plenum Publishing Corp., 1992).
Source link